Premier Health Approves Leadership and Stock Plan at 2026 AGM
Premier Health Approves Leadership and Stock Plan at 2026 AGM
Premier Health Approves Leadership and Stock Plan at 2026 AGM
Premier Health of America Inc. held its annual general meeting on March 26, 2026. The Canadian healthtech company, known for its LiPHe digital platform, put several key proposals to its shareholders for approval. At the meeting, shareholders voted on multiple resolutions. All matters presented were approved, including the election of three directors: Pierre-Luc Toupin, Hubert Marleau, and Jean-Robert Pronovost. The company also secured approval for its incentive Stock Option Plan, ensuring its continuation.
A total of 20,032,107 common shares were cast, accounting for 36.08% of the total shares issued. Additionally, shareholders re-appointed Raymond Chabot Grant Thornton LLP as the company's auditor. Premier Health specialises in outsourced healthcare solutions and digital transformation. Its LiPHe platform is designed to improve patient access by offering faster, more affordable, and widely available care services.
The annual general meeting concluded with all proposed measures passing successfully. The company will now move forward with its approved leadership, auditor, and stock option plan in place. No immediate updates on market performance are available following the meeting.
New white paper demands digital revolution in adult social care to save the NHS
The NHS's survival may hinge on fixing a broken system. Experts warn that without urgent digital upgrades in adult social care, the 10-Year Plan risks failure. Can AI, predictive tools, and smarter funding turn the tide?
Florida cracks down on deadly 7-OH drug after 587 overdose deaths
A synthetic opioid called 7-OH is flooding Florida's streets, disguised in vape shops and gas stations. Now, authorities are fighting back with felony charges and mass seizures.
Kazakhstan's Top Cardiology Institute Earns Elite Hypertension Accreditation
A landmark achievement for Central Asia's medical field. How this elite designation could transform heart health research and treatment in Kazakhstan.
RQ Bio Secures Funding to Revolutionize Flu Prevention with Single-Dose Antibody
A game-changing flu therapy is on the horizon. With fresh backing from top investors, RQ Bio's RQB01 promises season-long protection—and could redefine how we fight influenza.